Large scale production of Appethyl 2 as a biological appetite suppressant
|Funding from Vinnova||SEK 1 909 000|
|Project duration||September 2018 - April 2021|
|Venture||The strategic innovation programme Bioinnovation|
|Call||Key Enabling Technologies for production of biobased products|
Purpose and goal
Over 2 billion people are regarded as overweight globally of which ca one fourth are classified as obese. The project is based on green leaves as raw material for production of a group of products scientifically demonstrated to have effect in the application of appetite regulation and weight control. The difficulty is to produce the active ingredient with such purity that it can easily be formulated into consumer products. The aim is to reduce the daily dosage from 5 to 2 grams which would lead to considerable costumer benefits and opens up for development of new products and applications.
Expected results and effects
Lab tests using novel solutions of two process steps have shown that the active ingredient can be increased in concentration considerably. Up-scaling of these process steps into pilot industrial scale is expected to define new techniques for large scale production of the ingredient. The innovation is expected to result in new measures of appetite regulation and weight control that can be reached by a larger number of people.
Planned approach and implementation
The project will be conducted in cooperation between GreenLeaf Medical AB, SwePharm AB and Lund University. The activities have been divided into work packages in: Process up-scaling, Ingredient verification and Consumer product & market development. SwePharms role is to scale up the process. The role of GreenLeaf Medical is to verify the production of the ingredient in large scale and to transform the innovation into novel products through their customer network. The role of Lund University is to verify the function of the ingredient after up-scaling the process technique.